AKT1 and neoplasm: Abel et al. observed [18] ERBB3 activation due to vemurafenib treatment; however they saw activation via FOXD3. Chandarlapaty et al. [54] identified ERBB3 activation in response to AKT inhibition via phosphorylated FOXO3 in cancer cell lines from multiple tumor types, which were resistant to AKT inhibition.